BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24037738)

  • 1. Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.
    Ren S; Xu J; Zhou T; Jiang H; Chen H; Liu F; Na R; Zhang L; Wu Y; Sun J; Yang B; Gao X; Zheng SL; Xu C; Ding Q; Sun Y
    Prostate; 2013 Dec; 73(16):1824-35. PubMed ID: 24037738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
    Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
    Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
    Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
    Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive performance of prostate cancer risk in Chinese men using 33 reported prostate cancer risk-associated SNPs.
    Zheng J; Liu F; Lin X; Wang X; Ding Q; Jiang H; Chen H; Lu D; Jin G; Hsing AW; Shao Q; Qi J; Ye Y; Wang Z; Gao X; Wang G; Chu LW; Ouyang J; Huang Y; Chen Y; Gao Y; Shi R; Wu Q; Wang M; Zhang Z; Hu Y; Sun J; Zheng SL; Gao X; Xu C; Mo Z; Sun Y; Xu J
    Prostate; 2012 Apr; 72(5):577-83. PubMed ID: 21796652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population.
    Na R; Ye D; Liu F; Chen H; Qi J; Wu Y; Zhang G; Wang M; Wang W; Sun J; Yu G; Zhu Y; Ren S; Zheng SL; Jiang H; Sun Y; Ding Q; Xu J
    Prostate; 2014 Nov; 74(15):1569-75. PubMed ID: 25176131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
    Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
    Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort.
    Zhu Y; Han CT; Chen HT; Liu F; Zhang GM; Yang WY; Xu JF; Ye DW
    Oncotarget; 2015 Sep; 6(26):22978-84. PubMed ID: 26011940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer risk-associated genetic markers and their potential clinical utility.
    Xu J; Sun J; Zheng SL
    Asian J Androl; 2013 May; 15(3):314-22. PubMed ID: 23564047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator?
    Butoescu V; Ambroise J; Stainier A; Dekairelle AF; Gala JL; Tombal B
    Prostate; 2014 Apr; 74(4):365-71. PubMed ID: 24265090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men.
    Na R; Liu F; Zhang P; Ye D; Xu C; Shao Q; Qi J; Wang X; Chen Z; Wang M; He D; Wang Z; Zhou F; Yuan J; Gao X; Wei Q; Yang J; Jiao Y; Ou-Yang J; Zhu Y; Wu Q; Chen H; Lu D; Shi R; Lin X; Jiang H; Wang Z; Jiang D; Sun J; Zheng SL; Ding Q; Mo Z; Sun Y; Xu J
    Prostate; 2013 Nov; 73(15):1623-35. PubMed ID: 24038036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
    Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
    Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between the Body Mass Index and Prostate Cancer at Biopsy is Modified by Genetic Risk: A Cross-Sectional Analysis in China.
    Zhang GM; Zhu Y; Chen HT; Han CT; Liu F; Xu JF; Ye DW
    Medicine (Baltimore); 2015 Oct; 94(42):e1603. PubMed ID: 26496266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
    Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
    Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer antigen 3 and genetic risk score as markers for the detection of prostate cancer in the Chinese population.
    Wei HM; Chen HT; Wang P; Wu YS; Na R; Liu F; Sun JS; Jiang DK; Lu DR; Xu J
    Asian J Androl; 2015; 17(1):168-70. PubMed ID: 25412674
    [No Abstract]   [Full Text] [Related]  

  • 16. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients.
    Kader AK; Sun J; Isaacs SD; Wiley KE; Yan G; Kim ST; Fedor H; DeMarzo AM; Epstein JI; Walsh PC; Partin AW; Trock B; Zheng SL; Xu J; Isaacs W
    Prostate; 2009 Aug; 69(11):1195-205. PubMed ID: 19434657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
    Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.
    Kader AK; Liss MA; Trottier G; Kim ST; Sun J; Zheng SL; Chadwick K; Lockwood G; Xu J; Fleshner NE
    Urology; 2015 Jan; 85(1):165-70. PubMed ID: 25530379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of six susceptibility Loci with prostate cancer in northern chinese men.
    Zhang YR; Xu Y; Yang K; Liu M; Wei D; Zhang YG; Shi XH; Wang JY; Yang F; Wang X; Liang SY; Zhao CX; Wang F; Chen X; Sun L; Zhu XQ; Zhu L; Yang YG; Tang L; Jiao HY; Huo ZH; Yang Z
    Asian Pac J Cancer Prev; 2012; 13(12):6273-6. PubMed ID: 23464444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Hsa-miR-23a rs3745453 variation with prostate cancer risk among Chinese Han population: A case-control study.
    Zhang M; Wang Y; Wang C; You Z; Chen S; Kong Q; Xu B; Liu C; Chen M
    Medicine (Baltimore); 2019 Dec; 98(52):e18523. PubMed ID: 31876746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.